Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVGBM in unmethylated glioblastoma
NCT05938387Phase 1Completed
- Sponsor
- CureVac
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, open-label trial of CVGBM in glioblastoma (GBM) and astrocytoma, sponsored by CureVac. Primary endpoints: Incidence of treatment-related adverse events at 1 year, Incidence of treatment-emergent adverse events at 1 year and 4 more. Started Jun 2023; status: completed.
02
Drugs
CVGBM
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT05938387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938387.